GHK-Cu is a tripeptide-copper complex (Gly-His-Lys bound to Cu²⁺) first isolated by Loren Pickart in 1973 from human plasma. Over five decades of literature has positioned it as one of the most-studied copper-binding peptides in dermal and wound-repair research. This review maps the mechanistic threads that recur across the GHK-Cu corpus.
Structure and copper coordination
The tripeptide Gly-His-Lys binds Cu²⁺ with high affinity through histidine imidazole nitrogen and adjacent backbone atoms. The complex acts as a physiological copper carrier — it is the form in which copper is shuttled into and between cells under normal conditions, and the form that fibroblasts and keratinocytes recognise at the membrane.
Plasma decline with age
Endogenous GHK-Cu plasma concentration declines from approximately 200 ng/mL in young adults to ~80 ng/mL by age 60 (Pickart, 2008). The decline is one of the most-cited motivations for exogenous research, with the hypothesis that supplementing the depleted carrier restores fibroblast function in older tissue.
Fibroblast modulation
GHK-Cu upregulates dermal fibroblast activity in research models. The literature reports:
- Increased type I collagen synthesis
- Upregulated decorin and elastin expression
- Increased glycosaminoglycan synthesis (hyaluronic acid, dermatan sulfate)
- Stimulated fibroblast proliferation in vitro at low nanomolar concentrations
The effect on ECM components is the basis for the “remodelling” framing in research literature — GHK-Cu does not just stimulate matrix production, it also influences matrix composition.
Matrix metalloproteinase regulation
A distinctive feature of GHK-Cu is bidirectional MMP modulation. The peptide increases MMP-2 expression while simultaneously inducing tissue inhibitor of metalloproteinases (TIMP-1, TIMP-2). The net effect is controlled remodelling rather than runaway degradation — a pattern that distinguishes GHK-Cu from non-physiological MMP activators.
Wound-healing models
Rodent full-thickness wound models and porcine excisional wound models report accelerated closure and improved tissue architecture with GHK-Cu administration (Maquart et al., 1993). The mechanism appears multifactorial: angiogenesis, fibroblast recruitment, anti-inflammatory cytokine shift, and ECM remodelling all contribute. Differentiation from naive scar tissue is observed histologically — better collagen organisation and reduced fibrosis markers.
Hair follicle research
GHK-Cu has been investigated as a follicle-stimulating agent in rodent and ex vivo human scalp models. Reported mechanisms include dermal papilla cell stimulation and follicular keratinocyte modulation. The clinical translation of this research remains limited but the in vitro signal is consistent.
Anti-inflammatory and antioxidant profile
The copper centre confers antioxidant activity — GHK-Cu scavenges hydroxyl radicals and reduces oxidative damage markers in skin research models. The peptide also dampens pro-inflammatory cytokine release (TNF-α, IL-1β) in dermal fibroblasts under stress.
Gene expression profiling
Microarray studies have reported GHK-Cu modulates expression of more than 4,000 genes in human dermal fibroblasts (Pickart et al., 2014), with a pattern that includes ECM, antioxidant defence, and cellular repair pathways. The breadth is unusual and continues to drive mechanism-of-action investigation.
Stability and reconstitution
GHK-Cu is supplied as a lyophilised blue-tinted powder (the colour is the copper complex). Reconstitution in bacteriostatic water at 1–2 mg/mL is typical for stability studies. The copper centre is sensitive to reducing conditions — avoid reducing agents in reconstitution buffers. Refrigerated reconstituted GHK-Cu retains potency for approximately 4 weeks.
Open research questions
- Comparative bioavailability of GHK-Cu vs free GHK peptide
- Long-term receptor adaptation under chronic exposure
- Translation of strong in vitro signals to clinical wound-healing outcomes
Chempeptides supplies HPLC-verified GHK-Cu with batch CoA — see the research catalogue for current availability.
Research use only. Literature summarised above is preclinical unless otherwise stated.